Robert Driscoll
Stock Analyst at Wedbush
(1.82)
# 3,108
Out of 4,876 analysts
161
Total ratings
28.17%
Success rate
-8.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Outperform | $36 | $5.67 | +534.92% | 9 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.18 | +238.98% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.02 | +488.24% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $36.91 | +81.52% | 5 | Apr 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.60 | +269.57% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.54 | +59.15% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.47 | +394.59% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $21.37 | +143.33% | 9 | Dec 17, 2024 | |
| TYRA Tyra Biosciences | Reiterates: Outperform | $28 | $9.10 | +207.69% | 8 | Oct 25, 2024 | |
| BDTX Black Diamond Therapeutics | Reiterates: Outperform | $16 | $2.35 | +580.85% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $7.95 | +277.36% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.08 | +1,937.04% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $7.40 | +589.19% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.63 | +699.23% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.76 | +363.92% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.68 | +556.72% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.84 | +168.60% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $5.01 | +159.48% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $23.15 | +219.65% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.56 | +212.50% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.49 | +369.80% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $2.25 | +255.56% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $0.36 | +2,108.11% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $52 | $9.33 | +457.34% | 5 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.13 | +27.80% | 4 | May 19, 2020 |
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $5.67
Upside: +534.92%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.18
Upside: +238.98%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.02
Upside: +488.24%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $36.91
Upside: +81.52%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.60
Upside: +269.57%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.54
Upside: +59.15%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.47
Upside: +394.59%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $21.37
Upside: +143.33%
Tyra Biosciences
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $9.10
Upside: +207.69%
Black Diamond Therapeutics
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.35
Upside: +580.85%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $7.95
Upside: +277.36%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.08
Upside: +1,937.04%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $7.40
Upside: +589.19%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.63
Upside: +699.23%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.76
Upside: +363.92%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.68
Upside: +556.72%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.84
Upside: +168.60%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $5.01
Upside: +159.48%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $23.15
Upside: +219.65%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.56
Upside: +212.50%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.49
Upside: +369.80%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $2.25
Upside: +255.56%
May 3, 2024
Reiterates: Outperform
Price Target: $8
Current: $0.36
Upside: +2,108.11%
Nov 8, 2023
Reiterates: Outperform
Price Target: $52
Current: $9.33
Upside: +457.34%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.13
Upside: +27.80%